Mereo Stock Leadership


USD 0.87  0.05  6.10%   

Mereo Biopharma employes about 49 people. The company is managed by 13 executives with total tenure of roughly 14 years, averaging almost 1.0 years of service per executive having 3.77 employees per reported executive. Inspection of Mereo Biopharma management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Mereo Biopharma Group future performance.
Additionally, see Correlation Analysis.
  Denise ScotsKnight  CEO
CEO, Co-Founder, Executive Director
  Peter Fellner  Chairman
Independent Non-Executive Chairman of the Board

Mereo Biopharma Management Team Effectiveness

Mereo Biopharma Group has return on total asset (ROA) of (13.82) % which means that it has lost $13.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 34.85 %, meaning that it created $34.85 on every $100 dollars invested by stockholders. Mereo Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Mereo Biopharma Workforce Comparison

Mereo Biopharma Group is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 3,049. Mereo Biopharma claims roughly 49.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.

Mereo Biopharma Profit Margins

The company has Profit Margin (PM) of 34.9 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (57.42) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.57.

Mereo Biopharma Group Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Mereo Biopharma Group Price Series Division is a division of Mereo Biopharma price series and its benchmark/peer.

Mereo Biopharma Notable Stakeholders

A Mereo Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mereo Biopharma often face trade-offs trying to please all of them. Mereo Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mereo Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Alastair MacKinnon - Chief Medical Officer and Co-FounderProfile
John Richard - Head of Corporate Development and Co-FounderProfile
Charles Sermon - Co-Founder, General Counsel, SecretaryProfile
Denise ScotsKnight - CEO, Co-Founder, Executive DirectorProfile
Peter Fellner - Independent Non-Executive Chairman of the BoardProfile
Peter Bains - Non-Executive Independent DirectorProfile
Kunal Kashyap - Non-Executive DirectorProfile
Deepa Pakianathan - Non-Executive DirectorProfile
Paul Blackburn - Non-Executive Independent DirectorProfile
Michael Wyzga - Non-Executive DirectorProfile
Richard Jones - CFO, Executive DirectorProfile
Anders Ekblom - Non-Executive Independent DirectorProfile
Richard Francis - Head of Pharmaceutical DevelopmentProfile

About Mereo Biopharma Management Performance

The success or failure of an entity such as Mereo Biopharma Group often depends on how effective the management is. Mereo Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mereo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mereo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.
The data published in Mereo Biopharma's official financial statements usually reflect Mereo Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Mereo Biopharma Group. For example, before you start analyzing numbers published by Mereo accountants, it's critical to develop an understanding of what Mereo Biopharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Mereo Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mereo Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Mereo Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mereo Biopharma Group. Please utilize our Beneish M Score to check the likelihood of Mereo Biopharma's management to manipulate its earnings.

Mereo Biopharma Workforce Analysis

Traditionally, organizations such as Mereo Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mereo Biopharma within its industry.

Mereo Biopharma Manpower Efficiency

Return on Mereo Biopharma Manpower

Revenue Per Employee744.1 K
Revenue Per Executive2.8 M
Net Income Per Employee259.6 K
Net Income Per Executive978.5 K
Additionally, see Correlation Analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
CEO Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.